Calendario›MIST›Etripamil
Etripamil
ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2
Ensayo de Milestone Pharmaceuticals Inc. en Atrial Fibrillation (del registro, en inglés).
Lo que ha anunciado la empresa
La empresa anunció que alcanzó su objetivo principal…royalties of up to 18% on future sales of etripamil in Greater China. The NMPA approval was based on data from the global pivotal Phase 3 RAPID study and the Phase 3 JX02002 study conducted in China. JX02002 met its primary endpoint, demonstrating that etripamil was significantly superior to placebo in converting PSVT to sinus rhythm within 30 minutes of treatment (hazard ratio = 3.002 [95% CI: 1.578, 5.711]; p = 0.0005). Overall…
En un 8-K del 3 sep 2026, en una frase que nombra «Etripamil». El documento en la SEC.
La empresa anunció que alcanzó su objetivo principal…In clinical studies, participants using etripamil were two times more likely to convert symptomatic PSVT to sinus rhythm and did so more than three times faster compared with placebo. The RAPID trial achieved its primary endpoint with 64% of those who self-administered etripamil (N=99) converting from PSVT to sinus rhythm within 30 minutes compared to 31% on placebo (N=85) (HR=2.62; p<0.001). At one hour, the benefit was demonstrated…
En un 8-K del 6 ene 2026, en una frase que nombra «Etripamil». El documento en la SEC.
- Fase
- Fase 2
- Estado
- Completado
- Participantes
- 69
- Centros
- 18
- Fin del objetivo primario
- ago 2023
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en nov 2020.
Qué mide
The Maximum Reduction in Ventricular Rate, Measured on Holter Monitoring, Within 60 Minutes From Drug Administration. (60 minutes post drug administration) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroMany patients with atrial fibrillation (AF) experience persistent tachycardia with episodes of rapid ventricular rate despite chronic treatment to reduce ventricular rate. The objectives of this study were to demonstrate the superiority of a nasal spray of etripamil over placebo in reducing ventricular rate in patients with AF; and to evaluate the safety and efficacy of etripamil nasal spray in participants with AF.
Más ensayos de MIST
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Etripamil NS | Fase 2 | Reclutando pacientes | jun 2027 (prevista) |
| Etripamil · ReVeRA-301 | Fase 3 | Reclutando pacientes | dic 2028 (prevista) |
| Etripamil NS 70 mg | Fase 3 | Completado | abr 2026 (real) |
| Etripamil NS | Fase 3 | Completado | ene 2023 (real) |
| Etripamil · NODE-301 | Fase 3 | Interrumpido | ene 2023 (real) |
| Etripamil NS 70 mg | Fase 3 | Interrumpido | nov 2020 (real) |
Todos los de MIST, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT04467905), actualizada en sep 2024.